Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18766716 | METHOD FOR TREATING CANCER CELLS WITH A CU/AG PARTICLE COMPOSITION | July 2024 | September 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18602710 | MULTISTAGE CALCINATION METHOD FOR MAKING HOLLOW SILICA SPHERES | March 2024 | August 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18599582 | METHOD FOR DECREASING COLORECTAL CANCER CELLS | March 2024 | June 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18545415 | SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NEUROTROPHIC AND NEUROPROTECTIVE COMPOSITIONS | December 2023 | April 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18541054 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | December 2023 | February 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18500167 | PLASMONIC ENHANCED MAGNETIC NANOPARTICLES HYPERTHERMIA | November 2023 | October 2025 | Abandon | 24 | 2 | 1 | No | No |
| 18374334 | HOLLOW SILICA SPHERES WITH NESTED IRON OXIDE PARTICLES | September 2023 | February 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18231862 | NANOCOMPOSITE COMPOSITIONS COMPRISING MULTI-VALENT METAL MATERIAL AND IMMOBILIZED QUAT MATERIAL, METHODS OF MAKING THE COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS | August 2023 | February 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18366927 | SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR PHARMACEUTICAL COMPOSITIONS | August 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18366945 | SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NUTRITIONAL AND NUTRACEUTICAL COMPOSITIONS | August 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18220560 | COMPOSITION FOR TREATING BONE LOSS | July 2023 | May 2025 | Abandon | 23 | 4 | 0 | No | No |
| 18220599 | COMPOSITION FOR TREATING BONE LOSS | July 2023 | January 2025 | Abandon | 18 | 3 | 0 | No | No |
| 18349753 | BIOLOGICALLY ACTIVE SUBSTANCE UNIFORMLY DISPERSED MICROSPHERE AND A SUSTAINED RELEASE FORMULATION COMPRISING THE SAME | July 2023 | February 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18348799 | EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOF | July 2023 | December 2025 | Allow | 29 | 2 | 1 | No | No |
| 18343812 | CANCER TREATING COMPOSITION CONTAINING COPPER-SILVER-PHOSPHATE NANOPARTICLES | June 2023 | May 2025 | Allow | 23 | 3 | 1 | Yes | No |
| 18343803 | COPPER-SILVER-PHOSPHATE NANOPARTICLE MANUFACTURING METHOD | June 2023 | January 2025 | Allow | 19 | 1 | 1 | No | No |
| 18200055 | HOLLOW SILICA SPHERES WITH NESTED IRON OXIDE PARTICLES | May 2023 | August 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18301505 | METHOD FOR KILLING COLORECTAL CANCER CELLS | April 2023 | November 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18025686 | MICROORGANISM TARGETED NANOFORMULATIONS COMPRISING ANTIMICROBIAL COMPONENT(S) | March 2023 | March 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18025408 | Nanoparticles To Improve Analytical Signal | March 2023 | March 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18024743 | LIPID NANOPARTICLES MANUFACTURING CHIP, LIPID NANOPARTICLES MANUFACTURING SYSTEM HAVING THE SAME, AND LIPID NANOPARTICLES MANUFACTURING METHOD | March 2023 | August 2025 | Allow | 29 | 4 | 1 | Yes | Yes |
| 18116820 | COMPOSITION FOR TREATING BONE LOSS | March 2023 | February 2025 | Abandon | 24 | 4 | 1 | No | No |
| 18169051 | CONTINUOUS RELEASE COMPOSITIONS MADE FROM HYALURONIC ACID, AND THERAPEUTIC APPLICATIONS OF SAME | February 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18020525 | ACTIVE AGENT RELEASE PARTICLE | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18016092 | VETERINARY COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF PROTOZOAN DISEASES AND METHODS OF PREPARATION THEREOF | January 2023 | November 2025 | Abandon | 34 | 0 | 1 | No | No |
| 18087137 | COMPOSITE IMPLANTS | December 2022 | January 2024 | Abandon | 13 | 1 | 1 | No | No |
| 18001398 | NANOSPHERE SIZE CONTROL BY VARYING THE RATIO OF COPOLYMER BLENDS | December 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18071733 | NANOEMULSION | November 2022 | October 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17926902 | COMPOSITE MATERIAL | November 2022 | February 2026 | Abandon | 39 | 1 | 1 | No | No |
| 17999384 | METHOD OF TREATING OBESITY-INDUCED GLUCOSE INTOLERANCE AND LIVER FIBROSIS | November 2022 | November 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17987391 | UPCONVERSION NANOPARTICLE, HYALURONIC ACID-UPCONVERSION NANOPARTICLE CONJUGATE, AND A PRODUCTION METHOD THEREOF USING A CALCULATION FROM FIRST PRINCIPLES | November 2022 | August 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17956887 | TREATMENT METHOD FOR COLON CANCER | September 2022 | April 2023 | Allow | 6 | 1 | 0 | No | No |
| 17956875 | TREATMENT METHOD FOR COLON CANCER | September 2022 | January 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 17903273 | Liquid Foundation Using Starch as Filler and Preparation Method thereof | September 2022 | October 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17823750 | METHOD FOR MAKING SOLID SILICA SPHERES | August 2022 | August 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17893633 | HYBRID FRAGRANCE ENCAPSULATE FORMULATION AND METHOD FOR USING THE SAME | August 2022 | June 2025 | Allow | 34 | 1 | 0 | No | No |
| 17821471 | BIOCOMPATIBLE PHOTOTHERMAL COMPOSITION FOR TREATMENT OF CANCER AND SKIN DISEASES | August 2022 | July 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17800066 | AMPHIPHILIC IMIQUIMOD-GRAFTED LAURYL GAMMA-POLYGLUTAMATE AND USE THEREOF | August 2022 | September 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17886329 | BIOMARKERS FOR NANOPARTICLE COMPOSITIONS | August 2022 | February 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17811296 | METHODS FOR TREATMENT OF BLADDER CANCER WITH GEMCITABINE | July 2022 | December 2025 | Allow | 41 | 4 | 0 | Yes | Yes |
| 17855758 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA | June 2022 | September 2025 | Abandon | 39 | 2 | 0 | No | Yes |
| 17786678 | Determining Capsule Specificity for Specific Cell Types | June 2022 | December 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17806839 | PEDIATRIC FORMULATION | June 2022 | March 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17827190 | LIGHT-CONTROLLABLE SELF-ASSEMBLED COMPLEX AND NANOSYSTEM INCLUDING THE SAME | May 2022 | December 2025 | Abandon | 43 | 4 | 1 | No | No |
| 17748197 | Polymer complex for anticancer immune therapy based on ultrasound comprising oxalate derivatives and Method of preparation thereof | May 2022 | February 2026 | Abandon | 45 | 5 | 1 | No | No |
| 17741464 | ANTIMICROBIAL NANO-DELIVERANT AND METHODS | May 2022 | August 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17737561 | NICOTINAMIDE ADENINE DINUCLEOTIDE ACTIVATOR AND USE THEREOF | May 2022 | October 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17661172 | CANNABINOID COMPOSITIONS AND PROCESSES FOR MAKING SAME | April 2022 | December 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17730820 | COMPOSITION, PARTICULATE MATERIALS AND METHODS FOR MAKING PARTICULATE MATERIALS | April 2022 | June 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17768132 | SUPERFINE COMPOUNDS AND PRODUCTION THEREOF | April 2022 | May 2025 | Abandon | 37 | 4 | 1 | Yes | No |
| 17715970 | STARCH-BASED DOUBLE-LOADED FUNCTIONAL NANO PARTICLE AS WELL AS PREPARATION METHOD AND APPLICATION | April 2022 | July 2024 | Allow | 27 | 1 | 1 | No | No |
| 17711863 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | April 2022 | February 2024 | Allow | 22 | 1 | 0 | No | No |
| 17761057 | BISPHOSPHONATE LOADED STARCH NANOPARTICLE | March 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17760537 | HAIR TREATMENT METHOD | March 2022 | September 2025 | Abandon | 42 | 2 | 0 | Yes | No |
| 17579087 | METHOD OF PREPARING NANOPARTICLES FOR CANCER TREATMENTS | January 2022 | January 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17627044 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | January 2022 | October 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17646670 | HIGH-DENSITY AND SHORT-CHAIN PEG MODIFIED NANO-SIZED CARRIERS AND THEIR USES | December 2021 | September 2025 | Abandon | 45 | 3 | 1 | No | No |
| 17561540 | METHODS FOR TREATMENT OF BLADDER CANCER WITH GEMCITABINE | December 2021 | February 2025 | Abandon | 38 | 2 | 0 | Yes | Yes |
| 17552412 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | December 2021 | January 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17519900 | Esteramine Compositions | November 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17604138 | METHOD FOR REMOVING BIOFILM | October 2021 | May 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17389680 | OPHTHALMIC COMPOSITIONS FOR REMOVING MEIBUM OR INHIBITING MEIBUM BUILDUP | July 2021 | March 2025 | Abandon | 44 | 3 | 1 | No | No |
| 17384126 | LASER ENHANCER COMPOSITION FOR IMPROVING MELASMA, WRINKLES, SKIN TIGHTENING, PORES, AND ACNE | July 2021 | February 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17383161 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS | July 2021 | October 2025 | Abandon | 51 | 5 | 0 | No | No |
| 17351337 | NANOPARTICLE-ENCAPSULATED CANNABINOIDS AND METHODS FOR MAKING AND USING SAME | June 2021 | November 2024 | Abandon | 41 | 3 | 1 | No | No |
| 17352245 | PREPARATION OF NANOPARTICLES USING MODIFIED ICE-TEMPLATE | June 2021 | February 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17332175 | POLY(AMINE-CO-ESTER) POLYMERIC PARTICLES FOR SELECTIVE PULMONARY DELIVERY | May 2021 | November 2025 | Abandon | 54 | 4 | 1 | No | Yes |
| 17318339 | MULTI-COATED NANOPARTICLES COMPRISING MULTIPLE COATING LAYERS OF CHITOSAN AND POLYGLUTAMIC ACID, COMPOSITION FOR SKIN CARE COMPRISING THE SAME AND METHOD FOR MANUFACTURING THE SAME | May 2021 | April 2025 | Allow | 47 | 4 | 1 | Yes | No |
| 17306403 | DISSOLVING FILM FOR DELIVERY OF AN ACTIVE AGENT | May 2021 | October 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17244828 | NANOPARTICLE DELIVERY TO A TARGET TISSUE | April 2021 | August 2025 | Abandon | 52 | 4 | 1 | No | No |
| 17240405 | Nanoparticle Depot For Controlled And Sustained Gene Delivery | April 2021 | January 2025 | Abandon | 45 | 4 | 0 | Yes | No |
| 17239262 | NANOEMULSION HYDROPHOBIC SUBSTANCES | April 2021 | February 2023 | Abandon | 22 | 3 | 1 | Yes | No |
| 17231231 | METHODS OF TREATMENT USING TITANIUM AND SILVER NANOPARTICLES MADE WITH AN INTRACELLULAR EXTRACT OF FOMES FOMENTARIOUS | April 2021 | September 2023 | Abandon | 29 | 2 | 1 | Yes | No |
| 17228224 | DUAL-TARGETING LIPID-POLYMER HYBRID NANOPARTICLES | April 2021 | November 2024 | Abandon | 43 | 4 | 1 | No | No |
| 17205521 | METHOD FOR TREATMENT OF CORONAVIRUS INFECTION | March 2021 | April 2025 | Abandon | 49 | 3 | 1 | No | Yes |
| 17200540 | Injectable Therapeutic Biocompatible Co-Polymers and Methods of Making and Using Same | March 2021 | October 2025 | Abandon | 56 | 3 | 1 | No | Yes |
| 17188401 | PHARMACEUTICAL COMPOSITIONS OF RIVAROXABAN | March 2021 | September 2024 | Abandon | 43 | 3 | 1 | No | No |
| 17178808 | POLYMER-CYCLIC MOLECULE STRUCTURE AND METHOD FOR PRODUCING THE SAME | February 2021 | September 2024 | Abandon | 43 | 3 | 1 | Yes | No |
| 17267187 | INJECTABLE PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR | February 2021 | December 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17259371 | A BIOLOGICALLY ACTIVE SUBSTANCE UNIFORMLY DISPERSED MICROSPHERE AND A SUSTAINED RELEASE FORMULATION COMPRISING THE SAME | January 2021 | November 2023 | Abandon | 34 | 4 | 0 | Yes | No |
| 17136251 | METAL EXTRACTION SHEET, MASK PACK INCLUDING SAME AND METHOD FOR MANUFACTURING THE METAL EXTRACTION SHEET | December 2020 | August 2024 | Abandon | 43 | 3 | 1 | Yes | No |
| 16973721 | USE OF PHOSPHORUS-BASED MATERIAL IN PREPARATION OF MEDICAMENT FOR TREATING TUMORS | December 2020 | December 2024 | Abandon | 48 | 2 | 1 | Yes | No |
| 17106625 | PHARMACEUTICAL COMPOSITION COMPRISING AN ATYPICAL ANTIPSYCHOTIC AGENT AND METHOD FOR THE PREPARATION THEREOF | November 2020 | April 2022 | Abandon | 17 | 1 | 1 | No | No |
| 17079214 | CANNABINOID-CONTAINING ORAL THIN FILM FORMULATIONS | October 2020 | May 2022 | Abandon | 19 | 2 | 0 | Yes | No |
| 17070311 | PLASMONIC ENHANCED MAGNETIC NANOPARTICLES HYPERTHERMIA | October 2020 | December 2025 | Abandon | 60 | 8 | 1 | Yes | No |
| 17067297 | CONTINUOUS RELEASE COMPOSITIONS MADE FROM HYALURONIC ACID, AND THERAPEUTIC APPLICATIONS OF SAME | October 2020 | April 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17041094 | Poly (Alkyl Cyanoacrylate) Nanoparticles for Use in Treatment of Cancer | September 2020 | March 2026 | Abandon | 60 | 6 | 1 | Yes | No |
| 16990634 | CORE-SHELL STRUCTURE, PREPARATION, MEDICINE FOR EXTERNAL APPLICATION, TAPE AGENT AND COSMETIC PRODUCT | August 2020 | September 2024 | Allow | 49 | 2 | 0 | Yes | Yes |
| 16931939 | PRODUCTION OF NANOPARTICLES | July 2020 | May 2023 | Abandon | 34 | 2 | 1 | No | No |
| 16932699 | CANNABINOID COMPOSITIONS AND PROCESSES FOR MAKING SAME | July 2020 | May 2022 | Abandon | 22 | 3 | 1 | Yes | No |
| 16925478 | DISPERSIBLE POWDER AND COSMETIC | July 2020 | March 2024 | Abandon | 44 | 3 | 0 | No | No |
| 16906028 | HYDROGEL INCLUSION COMPLEX INCLUDING PHYSIOLOGICALLY ACTIVE MATERIAL BOUND TO THERMOSENSITIVE POLY(PHOSPHAZENE) BY HOST-GUEST INTERACTION USING BETA-CYCLODEXTRIN AND USE THEREOF | June 2020 | May 2025 | Abandon | 58 | 4 | 1 | No | No |
| 16896259 | Multi-Dose Concentrated Liquid Diphenhydramine HCl Compositions and Packaged Multi-Dose Liquid Diphenhydramine HCl Formulations | June 2020 | November 2025 | Abandon | 60 | 2 | 0 | No | Yes |
| 16890172 | FUNCTIONAL MEMBER AND METHOD OF FABRICATING THE SAME | June 2020 | February 2023 | Abandon | 33 | 0 | 1 | No | No |
| 16884161 | HIGH ABSORPTION MINERALS | May 2020 | February 2025 | Abandon | 57 | 4 | 1 | Yes | No |
| 16880309 | COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS | May 2020 | July 2024 | Abandon | 50 | 4 | 0 | No | No |
| 16764551 | METAL-NUCLEIC ACID NANOPARTICLE, PREPARATION METHOD THEREFOR AND USE THEREOF | May 2020 | July 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16760183 | RADIATION STERILIZED HYDROGELS, MEDICAL DEVICES INCLUDING RADIATION STERILIZED HYDROGELS AND METHODS OF MAKING THE SAME | April 2020 | January 2025 | Abandon | 56 | 3 | 1 | No | Yes |
| 16850468 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA | April 2020 | March 2022 | Allow | 23 | 1 | 0 | No | No |
| 16652944 | WATER-BASED TISSUE ADHESIVES | April 2020 | November 2025 | Allow | 60 | 2 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GREENE, IVAN A.
With a 31.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GREENE, IVAN A works in Art Unit 1619 and has examined 596 patent applications in our dataset. With an allowance rate of 17.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.
Examiner GREENE, IVAN A's allowance rate of 17.1% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GREENE, IVAN A receive 3.26 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by GREENE, IVAN A is 48 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +6.4% benefit to allowance rate for applications examined by GREENE, IVAN A. This interview benefit is in the 33% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 3.5% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 9.2% of cases where such amendments are filed. This entry rate is in the 9% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 34.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 45.2% of appeals filed. This is in the 11% percentile among all examiners. Of these withdrawals, 21.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 62.7% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.7% of allowed cases (in the 63% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.